<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00321724</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01825</org_study_id>
    <secondary_id>NCCTG-N048F</secondary_id>
    <secondary_id>U10CA025224</secondary_id>
    <secondary_id>CDR0000467560</secondary_id>
    <nct_id>NCT00321724</nct_id>
  </id_info>
  <brief_title>AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase II Trial of AZD2171 in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well AZD2171 works in treating patients with relapsed or&#xD;
      refractory B-cell chronic lymphocytic leukemia. AZD2171 may stop the growth of cancer cells&#xD;
      by blocking some of the enzymes needed for cell growth and by blocking blood flow to the&#xD;
      cancer cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Evaluate the response rate in patients with relapsed or refractory B-cell chronic&#xD;
      lymphocytic leukemia (B-CLL) treated with AZD2171.&#xD;
&#xD;
      II. Evaluate the toxicity of AZD2171 in patients with relapsed or refractory B-CLL.&#xD;
&#xD;
      III. Evaluate the complete response rate, progression-free and overall survival&#xD;
      distributions, and duration of response in patients with relapsed or refractory B-CLL treated&#xD;
      with AZD2171.&#xD;
&#xD;
      IV. Assess vascular endothelial growth factor receptor-2 (VEGFR-2) protein and&#xD;
      phosphorylation levels in B-CLL cells using pretreatment samples and evaluate the association&#xD;
      between Rai stage at study entry and clinical response to AZD2171.&#xD;
&#xD;
      V. Perform preclinical testing of AZD2171 in the induction of B-CLL cell apoptosis/cell death&#xD;
      using pretreatment samples, and evaluate the ability to downregulate the phosphorylation&#xD;
      status of VEGFR-2 of B-CLL cells by comparing in vitro samples with and without AZD2171.&#xD;
&#xD;
      VI. Study the differences in in vitro levels of B-CLL cell apoptosis/cell death and&#xD;
      alteration of VEGFR-2 phosphorylation using pretreatment samples with and without AZD2171 and&#xD;
      how these differences correlate with clinical outcomes.&#xD;
&#xD;
      VII. Assess if the clinical responses are associated with changes in bone marrow vascularity.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo blood sampling and biopsies at baseline and periodically throughout study&#xD;
      for biomarker and correlative studies.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically for up to 5 years from&#xD;
      study entry.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed response defined to be an objective status of complete remission [CR], nodular partial remission [nPR], and partial remission [PR]</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Ninety percent confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response rate estimated by the number of confirmed complete responses (CR) observed in the trial divided by the total number of evaluable patients</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Exact binomial 95% confidence intervals for the true complete response rate will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the date of registration to the date of death, assessed up to 5 years</time_frame>
    <description>Estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression as estimated by Kaplan-Meier method</measure>
    <time_frame>From the date of registration to the date of disease progression, assessed up to 5 years</time_frame>
    <description>Estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>From the date at which the patient's objective status is first noted to be a response to the date that progression or death is documented, assessed up to 5 years</time_frame>
    <description>Estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>B-cell Chronic Lymphocytic Leukemia</condition>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (cediranib maleate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cediranib maleate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (cediranib maleate)</arm_group_label>
    <other_name>AZD2171</other_name>
    <other_name>Recentin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (cediranib maleate)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological confirmation of B-cell chronic lymphocytic leukemia (B-CLL)&#xD;
&#xD;
               -  Peripheral blood lymphocyte count &gt; 5,000/mm³&#xD;
&#xD;
               -  Small to moderate peripheral blood lymphocytes with ≤ 55% prolymphocytes&#xD;
&#xD;
               -  Bone marrow aspirate with ≥ 30% lymphoid cells&#xD;
&#xD;
               -  Monoclonality of B lymphocytes by immunophenotyping, demonstrating all of the&#xD;
                  following:&#xD;
&#xD;
                    -  B-cell markers with CD5 antigen in the absence of other pan-T-cell markers&#xD;
                       (CD3, CD2, etc.)&#xD;
&#xD;
                    -  CD19 and/or CD20&#xD;
&#xD;
                    -  Expression of CD23 on the CLL cells OR dim B-cell expression of kappa or&#xD;
                       lambda light chains&#xD;
&#xD;
          -  Disease must be refractory to or progressive after treatment with at least 1 course&#xD;
             containing a purine nucleoside analog (e.g., fludarabine, cladribine, or pentostatin)&#xD;
&#xD;
          -  Life expectancy &gt; 6 months&#xD;
&#xD;
          -  ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 50,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 8 g/dL&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
               -  Patients with Gilbert's syndrome may have a bilirubin ≥ 1.5 times ULN&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No history of allergies to compounds similar to AZD2171&#xD;
&#xD;
          -  QTc prolongation &lt; 500 msec&#xD;
&#xD;
          -  No other significant ECG abnormality&#xD;
&#xD;
          -  No history of familial long QT syndrome&#xD;
&#xD;
          -  Proteinuria &lt; 1+ by dipstick OR protein &lt; 1 g/24 hr urine collection&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No New York Heart Association (NYHA) class III or IV disease&#xD;
&#xD;
               -  NYHA class II disease controlled with treatment and monitoring allowed&#xD;
&#xD;
          -  No other uncontrolled illness including, but not limited to, the following:&#xD;
&#xD;
               -  Hypertension&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Psychiatric illness or social situations that would limit compliance&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C),&#xD;
             radiotherapy, anti-vascular endothelial growth factor (VEGF) treatment, or major&#xD;
             surgery and recovered&#xD;
&#xD;
          -  More than 30 days since prior investigational agents&#xD;
&#xD;
          -  No concurrent drugs or biologics with proarrhythmic potential&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Kay</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Central Cancer Treatment Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Central Cancer Treatment Group</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>May 2, 2006</study_first_submitted>
  <study_first_submitted_qc>May 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2006</study_first_posted>
  <last_update_submitted>January 14, 2013</last_update_submitted>
  <last_update_submitted_qc>January 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cediranib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

